Pharmaceuticals

Pharmaceutical Safety Assessment Market Research: Growth Projections and Trends 2030

February 17, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the pharmaceutical safety assessment market from 2026–2035 with trusted insights from The Business Research Company

How is the Pharmaceutical Safety Assessment Market size predicted to change over the forecast window of 2026–2035?

The pharmaceutical safety assessment market size has exhibited strong growth in recent years. It is forecast to rise from $11.32 billion in 2025 to $12.24 billion in 2026, at a compound annual growth rate (CAGR) of 8.2%. This historical growth can be attributed to several factors, including the expansion of pharmaceutical R&D pipelines, increased regulatory scrutiny on drug safety, a rise in preclinical and clinical testing volumes, broader adoption of in-vitro safety assessment methods, and the growing utilization of CRO-led safety studies.

The pharmaceutical safety assessment market size is anticipated to experience substantial expansion in the coming years. This market is projected to reach $16.97 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.5%. This expansion during the forecast period is primarily driven by factors such as a greater dependence on computational safety assessment, the broadening development of personalized medicine, an escalating need for quicker regulatory approvals, the increasing incorporation of AI into drug safety processes, and more stringent post-market surveillance mandates. Key trends anticipated over this period encompass a rise in the deployment of AI-based tools for toxicity prediction, an increased embrace of in-silico safety assessment models, the expanding integration of real-time pharmacovigilance systems, the broadening of automated preclinical testing platforms, and a heightened emphasis on safety analytics that comply with regulations.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=29147&type=smp

Which Drivers Are Contributing To The Expansion Of The Pharmaceutical Safety Assessment Market?

The expansion of clinical trials is projected to stimulate the growth of the pharmaceutical safety assessment market in the coming years. Clinical trials involve research studies conducted in human subjects to assess the safety, effectiveness, and potential side effects of new medical treatments, drugs, or interventions. The increase in clinical trials stems from the growing necessity for new and effective treatments, as researchers and healthcare professionals strive to develop therapies that can more effectively prevent, manage, or cure diseases. These trials contribute to pharmaceutical safety assessment by systematically evaluating a drug’s effects on humans through carefully controlled studies, monitoring for adverse reactions, establishing safe dosage ranges, and providing essential data that regulatory authorities use to confirm that medications are both effective and safe for public consumption. For example, in September 2025, according to the National Library of Medicine (NLM), a US-based biomedical library, a total of 554,798 studies were registered on ClinicalTrials.gov as of September 26, 2025. Consequently, the expansion of clinical trials is a significant factor driving the growth of the pharmaceutical safety assessment market.

What Segment Classifications Make Up The Pharmaceutical Safety Assessment Market?

The pharmaceutical safety assessment market covered in this report is segmented –

1) By Type: In-Vitro Safety Assessment, In-Vivo Safety Assessment, Computational Safety Assessment

2) By Drug Type: Biological Drugs, Chemical Drugs

3) By Phase: Preclinical, Clinical (Phase I, II, III), Post-Market Surveillance (Phase IV)

4) By End User: Pharmaceutical Companies, Biotechnology Companies, Medical Device Companies, Academic And Research Institutions, Contract Research Organizations (CROs)

Subsegments:

1) By In-Vitro Safety Assessment: Cell-Based Assays, Organotypic Models, Tissue Culture Models, High-Throughput Screening

2) By In-Vivo Safety Assessment: Rodent Studies, Non-Rodent Studies, Toxicokinetic Studies, Carcinogenicity Studies

3) By Computational Safety Assessment: Quantitative Structure-Activity Relationship (QSAR) Modeling, Physiologically Based Pharmacokinetic (PBPK) Modeling, Toxicity Prediction Software, In Silico Simulation Studies

What Upcoming Trends Are Likely To Define The Future Path Of The Pharmaceutical Safety Assessment Market?

Key companies in the pharmaceutical safety assessment market are concentrating on developing AI-driven decision support tools to improve the accuracy and efficiency of toxicity prediction and safety profiling. An AI-powered decision support tool is a software system that utilizes artificial intelligence to analyze data and offer insights, supporting faster and more precise decision-making. For example, in April 2024, Charles River Laboratories, a US-based life sciences company, in collaboration with Deciphex, an Ireland-based company specializing in enhancing diagnostic precision and speed through AI-driven quality assurance, unveiled the Patholytix Foresight platform. This AI-powered decision support tool is specifically designed to transform toxicologic pathology in pharmaceutical safety assessment. The platform employs artificial intelligence to swiftly analyze intricate preclinical pathology data, assisting in the earlier identification of potential safety risks and decreasing subjectivity in results. It provides distinct features, including an AI algorithm for detecting tissue abnormalities, a cloud-based system facilitating global collaboration, and a scalable design that reduces slide review time while concurrently boosting data accuracy and consistency.

Which Leading Companies Dominate The Pharmaceutical Safety Assessment Market Share?

Major companies operating in the pharmaceutical safety assessment market are IQVIA Holding Inc., LabCorp (formerly Covance), Thermo Fisher Scientific (PPD), Charles River Laboratories, ICON plc, Parexel International Corp., Syneos Health, Eurofins Scientific SE, Wuxi Biologics Inc., SGS SA, Medpace Holdings Inc., Fujifilm Wako (Fujifilm Corp.), Pharmaron Beijing Co. Ltd., Inotiv (incl. Envigo), Evotec (Cyprotex), Intertek Group, Altasciences Inc., Aragen Life Sciences Ltd., CTI Clinical Trial and Consulting Inc., ChemDiv Inc., Frontage Laboratories, Medicilon Inc., Biotoxtech Co. Ltd., BioIVT, Accelera Srl.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/pharmaceutical-safety-assessment-global-market-report

How Does The Pharmaceutical Safety Assessment Market Perform Across Major Global Regions?

North America was the largest region in the pharmaceutical safety assessment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmaceutical safety assessment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Pharmaceutical Safety Assessment Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=29147&type=smp

Browse Through More Reports Similar to the Global Pharmaceutical Safety Assessment Market 2026, By The Business Research Company

Pharmaceutical Chemicals Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharmaceutical-chemicals-global-market-report

Pharmacovigilance Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharmacovigilance-global-market-report

Pharmaceuticals Market 2026

https://www.thebusinessresearchcompany.com/report/pharmaceuticals-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795